Atom | Request for Proposals: How Does Lebrikizumab Impact Post-inflammatory Dyspigmentation as Measured by the PDCA-Derm™ Scale in Patients With Moderate to Severe Atopic Dermatitis?

Due Dates: February 15, 2026

Funding Amounts: Amount and duration determined by proposal; financial support and/or study drug provided for selected projects.

Summary: Supports investigator-initiated clinical research on the effects of lebrikizumab on post-inflammatory dyspigmentation in moderate to severe atopic dermatitis, measured by the PDCA-Derm™ scale.

Key Information: Submission is via email; applicants must download and complete the proposal form from the program page.

Request for Proposals: How Does Lebrikizumab Impact Post-inflammatory Dyspigmentation as Measured by the PDCA-Derm™ Scale in Patients With Moderate to Severe Atopic Dermatitis?

Sign in to see full grant listing